MX2023003825A - Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. - Google Patents
Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados.Info
- Publication number
- MX2023003825A MX2023003825A MX2023003825A MX2023003825A MX2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A MX 2023003825 A MX2023003825 A MX 2023003825A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- thiadiazolone
- diabetes
- derivatives
- related disorders
- Prior art date
Links
- 101100321932 Rattus norvegicus Prkaa2 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- XWMXMWHHTIEXRE-UHFFFAOYSA-N thiadiazole 1-oxide Chemical class O=S1C=CN=N1 XWMXMWHHTIEXRE-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
- C07F9/65392—Five-membered rings containing two nitrogen atoms
- C07F9/65397—Five-membered rings containing two nitrogen atoms having the two nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2015585.9A GB202015585D0 (en) | 2020-10-01 | 2020-10-01 | New compounds |
| PCT/GB2021/052535 WO2022069894A1 (en) | 2020-10-01 | 2021-09-30 | Thiadiazolone derivatives and their use as ampk agonists for the treatment of diabetes and related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003825A true MX2023003825A (es) | 2023-06-06 |
Family
ID=73223766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003825A MX2023003825A (es) | 2020-10-01 | 2021-09-30 | Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230382930A1 (https=) |
| EP (1) | EP4222147B1 (https=) |
| JP (1) | JP7793614B2 (https=) |
| KR (1) | KR20230079163A (https=) |
| CN (1) | CN116368141B (https=) |
| AU (1) | AU2021352146A1 (https=) |
| CA (1) | CA3193947A1 (https=) |
| ES (1) | ES3018732T3 (https=) |
| GB (1) | GB202015585D0 (https=) |
| HU (1) | HUE071685T2 (https=) |
| MX (1) | MX2023003825A (https=) |
| PL (1) | PL4222147T3 (https=) |
| WO (1) | WO2022069894A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11691954B2 (en) | 2019-10-18 | 2023-07-04 | Betagenon Ab | Formulations |
| GB202112529D0 (en) * | 2021-09-02 | 2021-10-20 | Betagenon Bio Ab | New compounds |
| EP4600642A1 (en) * | 2022-10-05 | 2025-08-13 | Sawai Pharmaceutical Co., Ltd. | Method for selecting additive capable of inhibiting nitrosation reaction, and preparation prevented from generation of nitroso compound |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5982281B2 (ja) * | 2009-07-08 | 2016-08-31 | バルティック バイオ アーベー | 医薬として有用な化合物 |
| WO2013108026A1 (en) * | 2012-01-17 | 2013-07-25 | Baltic Bio Ab | Thiadiazolone derivatives useful in the treatment of diabetes |
| AU2018448511B2 (en) * | 2018-11-05 | 2025-07-03 | Betagenon Ab | Methods of treating diabetes in severe insulin-resistant diabetic subjects |
-
2020
- 2020-10-01 GB GBGB2015585.9A patent/GB202015585D0/en not_active Ceased
-
2021
- 2021-09-30 CN CN202180067894.4A patent/CN116368141B/zh active Active
- 2021-09-30 HU HUE21816508A patent/HUE071685T2/hu unknown
- 2021-09-30 WO PCT/GB2021/052535 patent/WO2022069894A1/en not_active Ceased
- 2021-09-30 EP EP21816508.2A patent/EP4222147B1/en active Active
- 2021-09-30 CA CA3193947A patent/CA3193947A1/en active Pending
- 2021-09-30 JP JP2023520459A patent/JP7793614B2/ja active Active
- 2021-09-30 ES ES21816508T patent/ES3018732T3/es active Active
- 2021-09-30 US US18/028,192 patent/US20230382930A1/en active Pending
- 2021-09-30 MX MX2023003825A patent/MX2023003825A/es unknown
- 2021-09-30 AU AU2021352146A patent/AU2021352146A1/en active Pending
- 2021-09-30 PL PL21816508.2T patent/PL4222147T3/pl unknown
- 2021-09-30 KR KR1020237014527A patent/KR20230079163A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3193947A1 (en) | 2022-04-07 |
| HUE071685T2 (hu) | 2025-09-28 |
| JP7793614B2 (ja) | 2026-01-05 |
| CN116368141A (zh) | 2023-06-30 |
| ES3018732T3 (en) | 2025-05-19 |
| PL4222147T3 (pl) | 2025-06-09 |
| EP4222147C0 (en) | 2025-03-19 |
| JP2023543924A (ja) | 2023-10-18 |
| EP4222147A1 (en) | 2023-08-09 |
| AU2021352146A1 (en) | 2023-06-01 |
| EP4222147B1 (en) | 2025-03-19 |
| GB202015585D0 (en) | 2020-11-18 |
| WO2022069894A1 (en) | 2022-04-07 |
| KR20230079163A (ko) | 2023-06-05 |
| US20230382930A1 (en) | 2023-11-30 |
| CN116368141B (zh) | 2025-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003825A (es) | Derivados de tiadiazolona y su uso como agonistas de ampk para el tratamiento de la diabetes y trastornos relacionados. | |
| MX2023013339A (es) | Inhibidor del factor b del complemento, y composicion farmaceutica del mismo, metodo de preparacion del mismo y uso del mismo. | |
| CO6382083A2 (es) | Compuestos triciclicos novedosos | |
| DOP2012000151A (es) | Nuevos compuestos triciclicos | |
| MX2020000261A (es) | Nuevos compuestos. | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| NI201200016A (es) | Derivados de piridina y pirazina como moduladores de cinasa de proteína | |
| ECSP099552A (es) | Compuestos triciclicos, composiciones y procedimientos | |
| CU20210035A7 (es) | Compuestos de azalactam como inhibidores de hpk 1 | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| UY35242A (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| UY31863A (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| CR20130530A (es) | Derivados glucósidos y sus usos para el tratamiento de la diabetes | |
| CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| DOP2025000212A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| BR112023012947A2 (pt) | Inibidores de lrrk2 | |
| ECSP13013026A (es) | Isoxazolinas como agentes terapéuticos | |
| PY1886949A (es) | Inhibidor del receptor del factor de crecimiento epidérmico | |
| MX2024001270A (es) | Compuestos heterociclicos para el tratamiento de la epilepsia. | |
| UY31824A (es) | Nuevos compuestos | |
| UY35223A (es) | Moduladores heterocíclicos de receptores de hormonas nucleares | |
| DOP2012000056A (es) | Agente terapeutico para trastornos de ansiedad | |
| MX2024002674A (es) | Derivados de tiadiazolona utiles como activadores de ampk. | |
| AR093043A1 (es) | Derivados de etinilo | |
| UY40025A (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno, y composiciones far |